Orgenesis Inc. (ORGS)
USD 2.36
(-9.23%)
USD 2.36
(-9.23%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 21.78 Million USD | 45.61% |
| 2022 | 14.96 Million USD | 134.98% |
| 2021 | 6.36 Million USD | 119.89% |
| 2020 | -32.01 Million USD | -339.12% |
| 2019 | 13.38 Million USD | 208.51% |
| 2018 | -12.33 Million USD | -395.76% |
| 2017 | 4.17 Million USD | -53.39% |
| 2016 | 8.95 Million USD | 46.46% |
| 2015 | 6.11 Million USD | 437.28% |
| 2014 | 1.13 Million USD | 433.43% |
| 2013 | 213.22 Thousand USD | 61547.55% |
| 2012 | -347.00 USD | 72.78% |
| 2011 | -1275.00 USD | 12.91% |
| 2010 | -1464.00 USD | 91.09% |
| 2009 | -16.42 Thousand USD | 70.14% |
| 2008 | -55 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 11.86 Million USD | -52.53% |
| 2024 Q1 | 27.26 Million USD | 25.17% |
| 2023 Q1 | 19.89 Million USD | 32.97% |
| 2023 FY | 21.78 Million USD | 45.61% |
| 2023 Q2 | 20.46 Million USD | 2.88% |
| 2023 Q3 | 21.69 Million USD | 6.0% |
| 2023 Q4 | 21.78 Million USD | 0.41% |
| 2022 Q4 | 14.96 Million USD | -41.75% |
| 2022 Q3 | 25.68 Million USD | 42.65% |
| 2022 Q1 | 10.74 Million USD | 68.75% |
| 2022 FY | 14.96 Million USD | 134.98% |
| 2022 Q2 | 18 Million USD | 67.58% |
| 2021 Q3 | -2.05 Million USD | 86.94% |
| 2021 Q4 | 6.36 Million USD | 410.28% |
| 2021 Q2 | -15.71 Million USD | 45.79% |
| 2021 FY | 6.36 Million USD | 119.89% |
| 2021 Q1 | -28.98 Million USD | 9.46% |
| 2020 Q2 | -86.13 Million USD | 9.44% |
| 2020 FY | -32.01 Million USD | -339.12% |
| 2020 Q1 | -95.11 Million USD | -810.4% |
| 2020 Q3 | -76.8 Million USD | 10.83% |
| 2020 Q4 | -32.01 Million USD | 58.32% |
| 2019 Q1 | 3.38 Million USD | 127.43% |
| 2019 Q2 | 4.77 Million USD | 41.22% |
| 2019 Q4 | 13.38 Million USD | 27.22% |
| 2019 FY | 13.38 Million USD | 208.51% |
| 2019 Q3 | 10.52 Million USD | 120.21% |
| 2018 Q3 | -13.92 Million USD | -735.15% |
| 2018 FY | -12.33 Million USD | -395.76% |
| 2018 Q4 | -12.33 Million USD | 11.37% |
| 2018 Q2 | -1.66 Million USD | -655.67% |
| 2018 Q1 | 300 Thousand USD | -92.81% |
| 2017 FY | 4.17 Million USD | -53.39% |
| 2017 Q2 | 7 Million USD | 6.3% |
| 2017 Q1 | 6.58 Million USD | -26.39% |
| 2017 Q4 | 4.17 Million USD | -42.41% |
| 2017 Q3 | 7.24 Million USD | 3.44% |
| 2016 FY | 8.95 Million USD | 46.46% |
| 2016 Q4 | 8.95 Million USD | 3.86% |
| 2016 Q1 | 6.61 Million USD | 8.2% |
| 2016 Q2 | 7.34 Million USD | 11.12% |
| 2016 Q3 | 8.61 Million USD | 17.29% |
| 2015 FY | 6.11 Million USD | 437.28% |
| 2015 Q2 | 9.08 Million USD | 353.56% |
| 2015 Q1 | 2 Million USD | 76.13% |
| 2015 Q3 | 9.86 Million USD | 8.53% |
| 2015 Q4 | 6.11 Million USD | -38.03% |
| 2014 Q1 | 133.39 Thousand USD | -37.44% |
| 2014 Q4 | 1.13 Million USD | 3.82% |
| 2014 Q2 | -12.38 Thousand USD | -109.29% |
| 2014 FY | 1.13 Million USD | 433.43% |
| 2014 Q3 | 1.09 Million USD | 8943.39% |
| 2013 Q1 | -50.01 Thousand USD | -14313.54% |
| 2013 FY | 213.22 Thousand USD | 61547.55% |
| 2013 Q4 | 213.22 Thousand USD | 182.61% |
| 2013 Q3 | -258.1 Thousand USD | 68.98% |
| 2013 Q2 | -832.02 Thousand USD | -1563.55% |
| 2012 Q2 | -127.28 Thousand USD | 64.02% |
| 2012 FY | -347.00 USD | 72.78% |
| 2012 Q4 | -347.00 USD | 99.89% |
| 2012 Q3 | -313.57 Thousand USD | -146.36% |
| 2012 Q1 | -353.78 Thousand USD | -27647.53% |
| 2011 FY | -1275.00 USD | 12.91% |
| 2011 Q1 | -7210.00 USD | -392.49% |
| 2011 Q2 | -6015.00 USD | 16.57% |
| 2011 Q3 | -5125.00 USD | 14.8% |
| 2011 Q4 | -1275.00 USD | 75.12% |
| 2010 Q2 | -7223.00 USD | 39.78% |
| 2010 Q1 | -11.99 Thousand USD | 26.97% |
| 2010 FY | -1464.00 USD | 91.09% |
| 2010 Q3 | -4483.00 USD | 37.93% |
| 2010 Q4 | -1464.00 USD | 67.34% |
| 2009 Q4 | -16.42 Thousand USD | 9.63% |
| 2009 Q3 | -18.17 Thousand USD | 0.0% |
| 2009 FY | -16.42 Thousand USD | 70.14% |
| 2008 FY | -55 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 138.942% |
| Alkermes plc | -166.73 Million USD | 113.065% |
| Agenus Inc. | 274.13 Million USD | 92.054% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 98.835% |
| Aptorum Group Limited | 1.35 Million USD | -1505.251% |
| Ardelyx, Inc. | 34.51 Million USD | 36.88% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | -408.972% |
| Bicycle Therapeutics plc | -481.46 Million USD | 104.525% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | 39.762% |
| ChromaDex Corporation | -24.04 Million USD | 190.585% |
| Chimerix, Inc. | -25.51 Million USD | 185.371% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -212.626% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 192.005% |
| CRISPR Therapeutics AG | -150.84 Million USD | 114.441% |
| Precision BioSciences, Inc. | -85.41 Million USD | 125.505% |
| Dyadic International, Inc. | -6.37 Million USD | 441.544% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 236.723% |
| Fortress Biotech, Inc. | 7.66 Million USD | -184.201% |
| Lantern Pharma Inc. | -21.7 Million USD | 200.372% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 119.707% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 354.987% |
| Incyte Corporation | -3.17 Billion USD | 100.686% |
| IO Biotech, Inc. | -140.69 Million USD | 115.483% |
| Jaguar Health, Inc. | 29.39 Million USD | 25.882% |
| Novavax, Inc. | -298.29 Million USD | 107.303% |
| Janux Therapeutics, Inc. | 5.33 Million USD | -308.169% |
| Opthea Limited | 28.15 Million USD | 22.635% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 229.752% |
| ContextLogic Inc. | -232 Million USD | 109.39% |
| MiMedx Group, Inc. | -33.9 Million USD | 164.258% |
| Pyxis Oncology, Inc. | 10.19 Million USD | -113.673% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 1040.17% |
| NextCure, Inc. | -6.47 Million USD | 436.329% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 143.136% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 441.496% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | -79.097% |
| Vaxcyte, Inc. | -368.22 Million USD | 105.916% |
| PDS Biotechnology Corporation | -32.7 Million USD | 166.6% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | -26.079% |
| Pharming Group N.V. | 109.8 Million USD | 80.161% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 225.224% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 112.432% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 217.625% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 217.625% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 406.817% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 471.741% |
| Acelyrin, Inc. | -216.9 Million USD | 110.043% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 488.288% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 1363.573% |
| Summit Therapeutics Inc. | 34.67 Million USD | 37.175% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 420.212% |
| Senti Biosciences, Inc. | 1.74 Million USD | -1151.954% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 111.8% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 128.126% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 459.353% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | -21734.438% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | -3368.79% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 118.611% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 112.949% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 80.352% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 386.783% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 116.872% |
| Psyence Biomedical Ltd. | 6.89 Million USD | -215.958% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 108.988% |
| Immix Biopharma, Inc. | -17.5 Million USD | 224.41% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 106.878% |
| MEI Pharma, Inc. | -3.7 Million USD | 687.962% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | -74.119% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 86.532% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | 21.621% |
| Fortress Biotech, Inc. | 7.66 Million USD | -184.201% |
| Precigen, Inc. | -481 Thousand USD | 4628.898% |
| Clearside Biomedical, Inc. | 14.08 Million USD | -54.705% |
| AlloVir, Inc. | -62.69 Million USD | 134.748% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 139.17% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 64.674% |
| ImmuCell Corporation | 10.99 Million USD | -98.206% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 114.132% |
| Onconetix, Inc. | 5.33 Million USD | -308.595% |
| PureTech Health plc | -167.19 Million USD | 113.029% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 171.517% |
| Elevation Oncology, Inc. | -19.11 Million USD | 213.945% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 543.756% |
| Seer, Inc. | -4.24 Million USD | 613.774% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 190.627% |
| Innoviva, Inc. | 255.56 Million USD | 91.476% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 138.995% |
| ESSA Pharma Inc. | -33.62 Million USD | 164.792% |
| GlycoMimetics, Inc. | -40.98 Million USD | 153.152% |
| GT Biopharma, Inc. | -1.02 Million USD | 2233.595% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 132.138% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 64.438% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 116.247% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 257.217% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 175.45% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | 29016.558% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 170.585% |
| Aptose Biosciences Inc. | -8.19 Million USD | 365.825% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 796.193% |
| Soligenix, Inc. | -4.95 Million USD | 539.939% |
| Century Therapeutics, Inc. | 847 Thousand USD | -2471.901% |
| Kura Oncology, Inc. | -20.11 Million USD | 208.281% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 153.228% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 359.395% |
| Ocean Biomedical, Inc. | 1.82 Million USD | -1095.809% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 781.389% |
| Autolus Therapeutics plc | -186.59 Million USD | 111.674% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 144.183% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 107.899% |
| Eterna Therapeutics Inc. | 34.26 Million USD | 36.43% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 86.747% |
| GRI Bio, Inc. | -1.79 Million USD | 1314.27% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 342.501% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 165.502% |
| IGM Biosciences, Inc. | -72.6 Million USD | 130.003% |
| INmune Bio, Inc. | -25.41 Million USD | 185.727% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 85.569% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 143.001% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 234.061% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 855.097% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | 42.696% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 152.893% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 31.679% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 94.236% |
| Verastem, Inc. | -37.27 Million USD | 158.437% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 340.097% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 142.004% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 243.931% |
| Histogen Inc. | -7.48 Million USD | 390.958% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 200.82% |
| Surrozen, Inc. | -32.66 Million USD | 166.691% |
| Organovo Holdings, Inc. | -1.5 Million USD | 1545.521% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 618.236% |
| Ovid Therapeutics Inc. | 18.96 Million USD | -14.893% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -732.722% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | -424.158% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 359.917% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 150.145% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 249.442% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 106.877% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | 3116.924% |
| Apollomics, Inc. | -27.39 Million USD | 179.518% |
| Amarin Corporation plc | -191.04 Million USD | 111.403% |
| Mesoblast Limited | 55.96 Million USD | 61.074% |
| Turnstone Biologics Corp. | -14.58 Million USD | 249.369% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 186.13% |
| Synaptogenix, Inc. | -28.66 Million USD | 176.004% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | 2427.35% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | 55.298% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 2626.885% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 399.804% |
| Exelixis, Inc. | -73.05 Million USD | 129.821% |
| Better Therapeutics, Inc. | -860 Thousand USD | 2633.023% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 190.718% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 109.025% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -2859.517% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 392.869% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -1637.161% |
| Gritstone bio, Inc. | 39.49 Million USD | 44.837% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 125.902% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 927.616% |
| Avid Bioservices, Inc. | 169.72 Million USD | 87.165% |
| Insmed Incorporated | 721.62 Million USD | 96.981% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 338.298% |
| MediWound Ltd. | -5.32 Million USD | 509.32% |
| OmniAb, Inc. | 9.2 Million USD | -136.705% |
| Alector, Inc. | -35.63 Million USD | 161.127% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 74.661% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 542.045% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | -64.544% |
| Zai Lab Limited | -775 Million USD | 102.811% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 93.603% |
| Aura Biosciences, Inc. | -21.52 Million USD | 201.203% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 126.411% |
| Immunic, Inc. | -45.34 Million USD | 148.046% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 111.274% |
| Veracyte, Inc. | -203.82 Million USD | 110.688% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 96.587% |
| FibroGen, Inc. | 56.76 Million USD | 61.626% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -144.627% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 870.547% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 1152.19% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 99.525% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 752.02% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 113.126% |
| TG Therapeutics, Inc. | 17.86 Million USD | -21.957% |
| Galecto, Inc. | -21.21 Million USD | 202.677% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 191.587% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 98.612% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 189.016% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 289.311% |
| XBiotech Inc. | -200.02 Million USD | 110.891% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 125.902% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | -381.095% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 161.776% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 128.211% |
| Theravance Biopharma, Inc. | 5.69 Million USD | -282.78% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 112.783% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 123.582% |
| Vaxxinity, Inc. | 10.13 Million USD | -115.002% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 97.041% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 302.312% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 133.028% |
| NexImmune, Inc. | -3.13 Million USD | 795.165% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 730.931% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 244.156% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 180.384% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 342.69% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 17586.655% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 153.692% |
| Ainos, Inc. | 4.07 Million USD | -434.193% |
| Pluri Inc. | 22.82 Million USD | 4.578% |
| Prothena Corporation plc | -608.34 Million USD | 103.581% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 118.343% |
| Celularity Inc. | 65.19 Million USD | 66.584% |
| Rallybio Corporation | -24.1 Million USD | 190.383% |
| Cue Biopharma, Inc. | -33.81 Million USD | 164.413% |
| MeiraGTx Holdings plc | -40.3 Million USD | 154.052% |
| Omeros Corporation | 331.17 Million USD | 93.422% |
| Humacyte, Inc. | -22.48 Million USD | 196.878% |
| Immunocore Holdings plc | -358.59 Million USD | 106.075% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 188.643% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 170.496% |
| Blueprint Medicines Corporation | 702.83 Million USD | 96.901% |
| CalciMedica, Inc. | -5.53 Million USD | 493.924% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 111.574% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 313.276% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 154.41% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 165.51% |
| Pulmatrix, Inc. | -10.41 Million USD | 309.12% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 464.464% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 157.113% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 119.554% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 136.341% |
| Cytokinetics, Incorporated | 642.37 Million USD | 96.609% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 474.103% |
| Nutriband Inc. | -251.65 Thousand USD | 8756.227% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 163.847% |
| Vor Biopharma Inc. | 4.3 Million USD | -406.605% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 100.361% |
| Evogene Ltd. | -19.63 Million USD | 210.95% |
| ProKidney Corp. | -56.23 Million USD | 138.737% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 144.757% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 335.829% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 98.403% |
| CorMedix Inc. | -43.05 Million USD | 150.599% |
| BioLineRx Ltd. | 7.33 Million USD | -196.947% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 179.315% |
| Galectin Therapeutics Inc. | 46.14 Million USD | 52.794% |
| Atai Life Sciences N.V. | -28.55 Million USD | 176.28% |
| Renovaro Biosciences Inc. | 2.23 Million USD | -876.629% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 195.477% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | -22.831% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 129.017% |
| MediciNova, Inc. | -50.78 Million USD | 142.896% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 127.643% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 96939.298% |
| GeoVax Labs, Inc. | -6.45 Million USD | 437.601% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 110.902% |
| Biomea Fusion, Inc. | -166.57 Million USD | 113.078% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 112.172% |
| Mereo BioPharma Group plc | -51.46 Million USD | 142.325% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 122.968% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 107.416% |
| Absci Corporation | -72.59 Million USD | 130.006% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -377.092% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 109.292% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 123.123% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 122.764% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 155.752% |
| Allakos Inc. | -24.97 Million USD | 187.223% |
| Imunon, Inc. | -4.21 Million USD | 616.962% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 247.768% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 116.089% |
| BioAtla, Inc. | -109.01 Million USD | 119.983% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -2859.517% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 2419.915% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | -82.049% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 202.74% |
| XOMA Corporation | -29 Million USD | 175.117% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 231.546% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 341.615% |
| aTyr Pharma, Inc. | -7.44 Million USD | 392.442% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 117.478% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 110.465% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 126.638% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 123.484% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | 2635.429% |
| Akari Therapeutics, Plc | -3.84 Million USD | 666.554% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -1242.297% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 98.422% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 1933.462% |
| UroGen Pharma Ltd. | 4.39 Million USD | -396.106% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 80.804% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -30171.532% |
| Entera Bio Ltd. | -10.62 Million USD | 304.949% |
| GH Research PLC | -78.07 Million USD | 127.901% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 197.739% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 181.713% |
| Xencor, Inc. | 29.64 Million USD | 26.515% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 1205.892% |
| Replimune Group, Inc. | 1.41 Million USD | -1442.776% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | 8994.769% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 117.232% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 1933.462% |
| Portage Biotech Inc. | -4.98 Million USD | 537.342% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 96939.298% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 132.945% |
| OncoCyte Corporation | -6.56 Million USD | 431.921% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | -2327.422% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 578.176% |
| Purple Biotech Ltd. | -14.13 Million USD | 254.081% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 191.699% |
| scPharmaceuticals Inc. | -6.54 Million USD | 432.834% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 230.504% |
| HilleVax, Inc. | -165.48 Million USD | 113.164% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 958.314% |
| Tharimmune, Inc. | -10.93 Million USD | 299.207% |
| Genprex, Inc. | -6.73 Million USD | 423.318% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 105.907% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 124.626% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 1654.889% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 756.749% |
| OKYO Pharma Limited | -826.84 Thousand USD | 2734.583% |
| Savara Inc. | 153 Thousand USD | -14137.908% |
| Curis, Inc. | -23.88 Million USD | 191.196% |
| Daré Bioscience, Inc. | -5.15 Million USD | 522.342% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | 2907.173% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 450.902% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | -1738.312% |
| BeiGene, Ltd. | -2.25 Billion USD | 100.967% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | -76.553% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 103.582% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 111.738% |
| Erasca, Inc. | -37.21 Million USD | 158.534% |
| bluebird bio, Inc. | 108.57 Million USD | 79.936% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 1791.445% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 94.248% |
| DBV Technologies S.A. | -126.98 Million USD | 117.155% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 1791.445% |
| Moderna, Inc. | -2.9 Billion USD | 100.749% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 310.433% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 300.442% |
| Molecular Templates, Inc. | 707 Thousand USD | -2981.188% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 169.44% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 93.715% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 126.546% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 123.748% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 167.501% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 163.37% |
| MacroGenics, Inc. | -66.98 Million USD | 132.521% |
| RenovoRx, Inc. | -1.17 Million USD | 1957.118% |
| Adicet Bio, Inc. | -138.78 Million USD | 115.696% |
| Prime Medicine, Inc. | -27.94 Million USD | 177.964% |
| Aditxt, Inc. | 18.12 Million USD | -20.215% |
| Adagene Inc. | -87.62 Million USD | 124.86% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 622.971% |
| Quantum-Si incorporated | -118.55 Million USD | 118.374% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | 39.497% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 391.456% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 144.907% |
| SciSparc Ltd. | -2.06 Million USD | 1154.915% |
| Vericel Corporation | 1.27 Million USD | -1605.873% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 281.659% |
| Minerva Neurosciences, Inc. | 41 Million USD | 46.874% |
| Generation Bio Co. | 31.44 Million USD | 30.73% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 112.422% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 170.446% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 81.316% |
| Invivyd, Inc. | -198.47 Million USD | 110.976% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 124.132% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 1008.542% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 130.773% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 419.179% |
| 2seventy bio, Inc. | 181.71 Million USD | 88.012% |
| ADMA Biologics, Inc. | 90.06 Million USD | 75.813% |
| Clene Inc. | 3.34 Million USD | -552.216% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 339.84% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 201.269% |
| GeoVax Labs, Inc. | -6.45 Million USD | 437.601% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 106.33% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 183.786% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 87.739% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 632.412% |
| Finch Therapeutics Group, Inc. | 5 Million USD | -335.506% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 518.199% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 116.718% |
| Evaxion Biotech A/S | 5.28 Million USD | -312.042% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 119.352% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 116.594% |
| Trevena, Inc. | 2.25 Million USD | -864.748% |
| Surrozen, Inc. | -32.66 Million USD | 166.691% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 142.291% |
| Cingulate Inc. | 3.08 Million USD | -606.657% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 841.709% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -203.103% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 334.458% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 127.462% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 116.572% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 120.64% |
| Clearmind Medicine Inc. | -3.94 Million USD | 652.524% |
| Kronos Bio, Inc. | -36.05 Million USD | 160.42% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | -131.523% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -1393.971% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 140.15% |
| Statera Biopharma, Inc. | 14.41 Million USD | -51.106% |
| ImmunityBio, Inc. | 618.22 Million USD | 96.476% |
| Korro Bio, Inc. | -132.94 Million USD | 116.386% |
| Kineta, Inc. | -4.54 Million USD | 579.718% |
| BioVie Inc. | -17.73 Million USD | 222.849% |
| Codexis, Inc. | -43.27 Million USD | 150.343% |
| Celularity Inc. | 65.19 Million USD | 66.584% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 787.409% |
| Celcuity Inc. | 6.78 Million USD | -221.132% |
| Virax Biolabs Group Limited | -3.36 Million USD | 747.381% |
| Cibus, Inc. | -8.07 Million USD | 369.671% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 615.11% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -376.674% |
| IN8bio, Inc. | -16.38 Million USD | 232.918% |
| Kodiak Sciences Inc. | -103.87 Million USD | 120.971% |
| Annexon, Inc. | -193.75 Million USD | 111.243% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | -60411.111% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 224.487% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 720.097% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 97.934% |
| Eyenovia, Inc. | 1.25 Million USD | -1630.672% |
| Puma Biotechnology, Inc. | 26.9 Million USD | 19.034% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 771.724% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 165.522% |
| Arcellx, Inc. | -296.95 Million USD | 107.336% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 211.678% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 137.0% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 205.1% |
| Moolec Science SA | 117.61 Thousand USD | -18421.29% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 156.731% |
| Geron Corporation | 14.76 Million USD | -47.578% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 157.45% |
| Royalty Pharma plc | 5.65 Billion USD | 99.615% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 115.404% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 411.671% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 506.201% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 115.479% |
| Humacyte, Inc. | -22.48 Million USD | 196.878% |
| Structure Therapeutics Inc. | -124.33 Million USD | 117.52% |
| 89bio, Inc. | -289.05 Million USD | 107.536% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 186.301% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 1321.761% |
| Genelux Corporation | -6.89 Million USD | 415.756% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 170.137% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 73.942% |
| Notable Labs, Ltd. | -9.77 Million USD | 322.831% |
| Liquidia Corporation | -80.17 Million USD | 127.17% |
| Mustang Bio, Inc. | -3.73 Million USD | 683.084% |
| Immunovant, Inc. | -635.22 Million USD | 103.429% |
| Quantum-Si incorporated | -118.55 Million USD | 118.374% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 224.026% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 625.803% |
| Vera Therapeutics, Inc. | 8.02 Million USD | -171.384% |
| Acasti Pharma Inc. | -23 Million USD | 194.692% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 746.941% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 234.061% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 115.815% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 799.02% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 197.985% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 217.314% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 112.869% |
| PepGen Inc. | -60.67 Million USD | 135.906% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 194.812% |
| United Therapeutics Corporation | -507.7 Million USD | 104.291% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 213.897% |
| Solid Biosciences Inc. | -47.75 Million USD | 145.621% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 2626.885% |
| Immuneering Corporation | -54.94 Million USD | 139.648% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 618.236% |
| Silo Pharma, Inc. | -3.52 Million USD | 718.107% |
| Belite Bio, Inc | -87.27 Million USD | 124.961% |
| XOMA Corporation | -29 Million USD | 175.117% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 130.813% |
| Bionomics Limited | 227 Million USD | 90.404% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 118.734% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 960.008% |
| uniQure N.V. | -102.95 Million USD | 121.16% |
| Cassava Sciences, Inc. | -121.13 Million USD | 117.983% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 622.971% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | 46.805% |
| Forte Biosciences, Inc. | -11.96 Million USD | 282.125% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 804.027% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | -20450.943% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 771.724% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -144.627% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 393.743% |
| Altimmune, Inc. | -134.48 Million USD | 116.198% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 89.002% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 960.008% |
| Compugen Ltd. | -12.9 Million USD | 268.816% |
| Peak Bio, Inc. | 10.34 Million USD | -110.674% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | 7797.527% |
| Benitec Biopharma Inc. | -50.58 Million USD | 143.067% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 120.878% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | -10.888% |
| Zura Bio Limited | -99.8 Million USD | 121.826% |
| PolyPid Ltd. | 6.17 Million USD | -253.063% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 70.61% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | -10.888% |
| Instil Bio, Inc. | 75.35 Million USD | 71.093% |
| argenx SE | -2.02 Billion USD | 101.074% |
| Immunome, Inc. | -97.02 Million USD | 122.451% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 196.839% |
| Verona Pharma plc | -220.44 Million USD | 109.882% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 130.364% |
| Shattuck Labs, Inc. | -121.42 Million USD | 117.94% |
| CervoMed Inc. | -7.79 Million USD | 379.538% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 111.743% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 598.148% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 116.536% |
| Moolec Science SA | 117.61 Thousand USD | -18421.29% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 1052.107% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | -37.02% |
| AnaptysBio, Inc. | -18.15 Million USD | 220.015% |
| Design Therapeutics, Inc. | -18.15 Million USD | 220.022% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 130.952% |
| NeurAxis, Inc. | 145.7 Thousand USD | -14851.27% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | -93.946% |
| Lumos Pharma, Inc. | -28.49 Million USD | 176.454% |
| Achilles Therapeutics plc | -126.92 Million USD | 117.163% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 130.364% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | 3422.099% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 204.863% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -1393.971% |
| Nutriband Inc. | -251.65 Thousand USD | 8756.227% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 265.394% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 392.796% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 93.597% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | 8.22% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 104.868% |
| Palisade Bio, Inc. | -12.06 Million USD | 280.585% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 115.526% |
| Beam Therapeutics Inc. | -262.72 Million USD | 108.292% |
| Neurogene Inc. | -131.95 Million USD | 116.509% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | 0.147% |
| AEON Biopharma, Inc. | -4.88 Million USD | 546.393% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 105.775% |
| Sesen Bio, Inc. | -112.55 Million USD | 119.354% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 121.815% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 1027.85% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 155.819% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 126.157% |
| Athira Pharma, Inc. | -88.99 Million USD | 124.477% |
| Vaccinex, Inc. | -1.28 Million USD | 1791.304% |
| HCW Biologics Inc. | 2.85 Million USD | -662.565% |
| XOMA Corporation | -29 Million USD | 175.117% |
| Nektar Therapeutics | 210.24 Million USD | 89.639% |
| Arvinas, Inc. | -313.8 Million USD | 106.942% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -1242.297% |
| Merus N.V. | -192.88 Million USD | 111.294% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 63.684% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 413.981% |
| Rezolute, Inc. | -68.16 Million USD | 131.956% |
| Clene Inc. | 3.34 Million USD | -552.216% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 265.193% |
| BeyondSpring Inc. | -13.75 Million USD | 258.372% |
| Synlogic, Inc. | -6.68 Million USD | 425.864% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | -1820.988% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 357.646% |
| Peak Bio, Inc. | 10.34 Million USD | -110.674% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 126.43% |
| Krystal Biotech, Inc. | -350.23 Million USD | 106.22% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 82.45% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 112.89% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 789.991% |
| MannKind Corporation | 143.89 Million USD | 84.862% |
| Ikena Oncology, Inc. | -109.15 Million USD | 119.957% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 387.729% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 165.813% |
| Gossamer Bio, Inc. | 180.35 Million USD | 87.922% |
| CohBar, Inc. | -5.93 Million USD | 467.307% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 173.228% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -377.092% |
| Legend Biotech Corporation | -949.39 Million USD | 102.295% |
| Mural Oncology plc | -255.84 Million USD | 108.515% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 32.379% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 562.442% |
| Disc Medicine, Inc. | -358.28 Million USD | 106.08% |
| Champions Oncology, Inc. | 4.81 Million USD | -352.702% |
| REGENXBIO Inc. | 54.76 Million USD | 60.225% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | 8200.942% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 114.424% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 341.722% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 126.999% |
| Vaxart, Inc. | -8.24 Million USD | 364.337% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 143.412% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 117.13% |
| Cellectis S.A. | -43.85 Million USD | 149.673% |
| Longeveron Inc. | -2.9 Million USD | 849.106% |
| Repare Therapeutics Inc. | -107.85 Million USD | 120.197% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 97.75% |
| Inozyme Pharma, Inc. | 12 Million USD | -81.473% |
| Revolution Medicines, Inc. | -608.2 Million USD | 103.582% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 1871.057% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 108.217% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 114.516% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 239.222% |
| Anixa Biosciences, Inc. | -740 Thousand USD | 3043.784% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 100.228% |
| Denali Therapeutics Inc. | -74.86 Million USD | 129.098% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 281.659% |
| Veru Inc. | 4.77 Million USD | -355.735% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 293.704% |
| Cingulate Inc. | 3.08 Million USD | -606.657% |
| Passage Bio, Inc. | 4.58 Million USD | -375.115% |
| Context Therapeutics Inc. | -14.44 Million USD | 250.756% |
| Exicure, Inc. | 5.84 Million USD | -272.44% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 109.456% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 155.052% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | -38.831% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 137.034% |
| Nuvalent, Inc. | -335.38 Million USD | 106.495% |
| ABVC BioPharma, Inc. | 1.73 Million USD | -1156.039% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 129.247% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 345.039% |
| OmniAb, Inc. | 9.2 Million USD | -136.705% |
| Anew Medical, Inc. | 1.43 Million USD | -1420.735% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | -32.977% |
| Lipocine Inc. | -4.75 Million USD | 558.168% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 119.835% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | -43.024% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 143.001% |
| G1 Therapeutics, Inc. | 24.89 Million USD | 12.486% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 424.118% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 133.093% |
| Ocugen, Inc. | -32.52 Million USD | 166.984% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 125.456% |
| Q32 Bio Inc. | -37.94 Million USD | 157.405% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | 3568.79% |
| Alumis Inc. Common Stock | -13.52 Million USD | 261.017% |
| Equillium, Inc. | -22.39 Million USD | 197.285% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 185.2% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 166.767% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | 8886.883% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 83.748% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -581.176% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -6532.546% |
| Dominari Holdings Inc. | 195 Thousand USD | -11071.282% |
| Edesa Biotech, Inc. | -5.26 Million USD | 513.601% |
| vTv Therapeutics Inc. | -8.91 Million USD | 344.297% |
| Bio-Techne Corporation | 267.74 Million USD | 91.864% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 234.394% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 118.446% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 359.241% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 272.192% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 108.887% |
| Nkarta, Inc. | 57.29 Million USD | 61.982% |
| BioCardia, Inc. | 212 Thousand USD | -10175.472% |
| Iterum Therapeutics plc | 13.43 Million USD | -62.107% |